Drug Type Chemical drugs |
Synonyms |
Mechanism EGFR C797S inhibitors(Epidermal Growth Factor Receptor C797S inhibitors), EGFR exon 19 deletion inhibitors, EGFR exon 21 L858R mutation inhibitors + [1] |
Therapeutic Areas |
Active Indication |
Inactive Indication- |
Originator Organization |
Active Organization |
Inactive Organization- |
Drug Highest PhasePreclinical |
First Approval Date- |
Regulation- |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Central Nervous System Neoplasms | Preclinical | US | 22 Mar 2024 |